



Surgical and Non-Surgical Causes of Progressive Hearing Loss in Children: What can be done about it?

Daniela Carvalho, MD, MMM, FAAP

Professor, Surgery Department – UCSD

Pediatric Otolaryngology

Rady Children's Hospital San Diego



WELL BEHAVED
WOMEN
RARELY MAKE
HISTORY





Pediatric Progressive Hearing Loss

- ▣ Non-surgical
 - ▣ Genetic

 - ▣ CMV
- ▣ Surgical
 - ▣ Tympanic membrane retraction → Cholesteatoma
 - ▣ Tympanosclerosis
 - ▣ Otosclerosis




Pediatric Progressive Hearing Loss

- ▣ Non-surgical
 - ▣ Genetic
 - ▣ Connexin 26 and Enlarged Vestibular Aqueduct
 - ▣ CMV
- ▣ Surgical
 - ▣ Tympanic membrane retraction → Cholesteatoma
 - ▣ Tympanosclerosis
 - ▣ Otosclerosis





Genetic causes of SNHL



Sloan-Heggen et al 2016; Smith et al, unpublished data

GJB2 (Connexin 26)

- ▣ DFNB1
- ▣ Gene: GJB2 (gap junction beta 2)
- ▣ Connexin 26: protein





GJB2 (Connexin 26)

- ▣ Hearing loss ranges from mild to profound
- ▣ Majority congenital

- ▣ More than 50% will have HL progression
 - ▣ generally gradual
 - ▣ occasionally precipitous
 - ▣ Influenced by genetics and other factors



GJB2 – Progressive hearing loss


- ▣ Kenna et al, 2010
- ▣ 126 patients with SNHL due to GJB2
 - ▣ 33% had bilateral profound SNHL when initially identified
 - ▣ 67% presented with mild to severe SNHL
 - ▣ 56% have had progression of their hearing loss
 - ▣ 3 of them possibly due to other causes



No. (%) of 225 Alleles Identified		Nontruncating	
Truncating		V37I	23 (9.4)
35delG		M34T	22 (9.1)
167delT		V84L	2 (0.8)
235delC		L90P	2 (0.8)
313_326del14bp		N206S	2 (0.8)
E47X		S199F	2 (0.8)
M1V		T8M	1 (0.4)
W24X		G12V	1 (0.4)
Q57X		K15T	1 (0.4)
176_191del16		R32C	1 (0.4)
299_300delAT		I35S	1 (0.4)
333_334delAA		V95M	1 (0.4)
453_460del8ins9 ^a		[E114G;V27I](in <i>cis</i>) ^b	1 (0.4)
631_632delGT		S139N	1 (0.4)
Total		R143W	1 (0.4)
		V153I	1 (0.4)
		R184P	1 (0.4)




GJB2 – Progressive hearing loss






GJB2 – Progressive hearing loss








GJB2 – Progressive hearing loss

Race/Ethnicity	Progressive HL	Non-progressive HL
White, non-Hispanic	40 (85%)	24 (65%)
White, Hispanic	3 (6%)	5 (14%)
Asian	2 (4%)	7 (19%)
African American and white	2 (4%)	0
Asian and white	1 (2%)	1 (3%)




GJB2 – Progressive hearing loss

Future



Enlarged Vestibular Aqueduct

The inner ear



Credit: NIH Medical Arts





Enlarged Vestibular Aqueduct





Enlarged Vestibular Aqueduct





Enlarged Vestibular Aqueduct

- ▣ Most common inner ear abnormality
- ▣ Normal size 0.4 - 1.0 mm
- ▣ Abnormal >1.5 mm at its midpoint
- ▣ Bilateral (up to 94%)



Enlarged Vestibular Aqueduct

- At birth
 - Normal to profound SNHL

- Progression
 - Can deteriorate into early adulthood (25 dB per 6 years)
 - Can have sudden decrements of hearing (65%) – can be related to head trauma/pressure changes



Enlarged Vestibular Aqueduct

- Ascha et al, JAMA 2017
- ▣ For each millimeter increase in vestibular aqueduct size (greater than 1.5 millimeters)
 - ▣ increase of 17.5 dB in speech reception threshold
 - ▣ decrease of 21% in word recognition scores
- ▣ For every year after the initial audiogram
 - ▣ speech recognition threshold increased by 1.5 dB
 - ▣ word recognition decreased by an additional 1.7%



Enlarged Vestibular Aqueduct

- Up to 1/3 patients with conductive component
 - Increased pressure dampening stapes
 - 3rd window effect
- Risk of CSF “gusher” with stapedectomy and cochlear implantation
 - Some have suggested increased incidence of PLF





Enlarged Vestibular Aqueduct

- *Pendred syndrome versus Nonsyndromic enlarged vestibular aqueduct (PDS/NSEVA)*
- Phenotypic spectrum:
 - Sensorineural hearing loss (SNHL)
 - Vestibular dysfunction
 - Temporal bone abnormalities (bilateral enlarged vestibular aqueduct with or without cochlear hypoplasia)
 - PDS also includes development of euthyroid goiter in late childhood to early adulthood

Enlarged Vestibular Aqueduct

- Pendred syndrome
 - 50% with euthyroid goiter
 - EVA with/without cochlear hypoplasia (1.5 turns)
- NSEVA
 - No goiter
 - Only EVA present, no cochlear hypoplasia





Enlarged Vestibular Aqueduct

- Autosomal recessive
 - Biallelic pathogenic variants in *SLC26A4* or
 - double heterozygosity (*SLC26A4* and either *FOXI1* or *KCNJ10*)



Enlarged Vestibular Aqueduct

- ▣ Treatment of manifestations:
 - ▣ Hearing loss
 - ▣ Goiter/hypothyroidism






Enlarged Vestibular Aqueduct

- ▣ Surveillance:
 - ▣ Audio every 3-6 months initially, then 6-12 months
 - ▣ Baseline ultrasound examination of the thyroid
 - ▣ Monitor volumetric changes (clinical and/or US)
- ▣ Agents/circumstances to avoid:
 - ▣ Dramatic increases in intracranial pressure can be associated with a sudden drop in hearing
 - Avoiding weightlifting and/or contact sports should be discussed with a physician

TM retraction / Cholesteatoma




Cholesteatoma - progression






Cholesteatoma - progression





Retracted Tympanic Membrane

- ▣ What can be done?





Retracted Tympanic Membrane





Retracted Tympanic Membrane






Cholesteatoma









Otologic surgery






Otologic surgery









Wide endoscopic
field of view




Microscope versus Endoscope







Endoscopic view






Hard-to-reach areas




Hard-to-reach areas

- ▣ Sinus tympani
- ▣ Facial recess
- ▣ Hypotympanum
- ▣ Attic
- ▣ Anterior epitympanum





Hard-to-reach areas





Cholesteatoma





Cholesteatoma






Cholesteatoma recurrence

- ▣ Recurrence rate
 - ▣ Endoscopic = 8.6%
 - ▣ Canal-wall-up mastoidectomy = up to 25%



Set up






Middle ear exploration





Anterior retraction/cholesteatoma





Anterior retraction/cholesteatoma





Ossicular Reconstruction





Ossicular Reconstruction







Houston, November 30 – December 2, 2018

San Diego, 2019



Thank you!

